CJC-1295 vs Rusfertide
Overview
CJC-1295 is primarily a performance & growth peptide, while Rusfertide is used for weight management & metabolic.
This page compares CJC-1295 and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Rusfertide | |
|---|---|---|
| Category | Performance & Growth | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | 19-108 mg |
| Frequency | weekly | once weekly, subcutaneous |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Rusfertide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Rusfertide: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Rusfertide?
- CJC-1295 is primarily a performance & growth peptide, while Rusfertide is used for weight management & metabolic. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Rusfertide is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take CJC-1295 and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Rusfertide FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references